SAO PAULO (Reuters) - Preliminary data from a study in Brazil indicates that the COVID-19 vaccine developed by China’s Sinovac Biotech Ltd is effective against the P1 variant of the virus first discovered in Brazil, a source familiar with the study told Reuters on Monday.
The source, who did not provide data details, said the study had tested the blood of vaccinated people against the Brazilian variant of the virus. Coronavac, as the Sinovac shot is known, is the main vaccine currently being used to inoculate people in Brazil.
- DigitALL: Innovation And technology For Gender Equality
- Mar 08, 2023
- India Says It Will Protect Its Interests As Chinese Boat Heads To Sri Lanka
- Jul 30, 2022
- Omicron Poses 'Very High' Global Risk, World Must Prepare: WHO
- Nov 29, 2021
- Resumption Of India's COVAX Vaccine Supply Delayed By Nepal
- Nov 24, 2021
- US Shipping 1.5 Million J&J Vaccines To Nepal
- Jul 10, 2021
